Deciphera’s $400M follow-on adds firepower on strength of GIST readout
Deciphera’s offering shows investor demand is strong for companies with late-stage success stories
Outsized investor demand continues unabated for stocks of companies with late stage clinical success stories, as evidenced by Deciphera’s ability to double the size of its follow-on to $400 million with little to no haircut despite turbulent macroeconomic headwinds.
On the strength of a gastrointestinal cancer readout that led to an 80% gain
